Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through 2043 - SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRDF), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback